MiMedx Company Top Insiders
MDXG Stock | USD 7.89 0.21 2.59% |
MiMedx's insiders are aggressively selling. The analysis of the overall insider sentiment regarding MiMedx Group suggests that almost all insiders are panicking. MiMedx employs about 837 people. The company is managed by 15 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 55.8 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2025-03-10 | William Frank Iv Hulse | Disposed 81446 @ 7.8 | View | ||
2025-02-28 | Kimberly Maersk-Moller | Disposed 2111 @ 8.4 | View | ||
2024-03-13 | William Frank Iv Hulse | Disposed 20381 @ 7.95 | View |
Monitoring MiMedx's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
MiMedx |
MiMedx's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with MiMedx's future performance. Based on our forecasts, it is anticipated that MiMedx will maintain a workforce of roughly 840 employees by April 2025.MiMedx Management Team Effectiveness
The company has return on total asset (ROA) of 0.1474 % which means that it generated a profit of $0.1474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2501 %, meaning that it created $0.2501 on every $100 dollars invested by stockholders. MiMedx's management efficiency ratios could be used to measure how well MiMedx manages its routine affairs as well as how well it operates its assets and liabilities. At this time, MiMedx's Return On Assets are most likely to increase slightly in the upcoming years. At this time, MiMedx's Return On Tangible Assets are most likely to increase slightly in the upcoming years. The MiMedx's current Return On Assets is estimated to increase to 0.17, while Non Currrent Assets Other are projected to decrease to roughly 666.9 K.The current Common Stock Shares Outstanding is estimated to decrease to about 98.3 M. The MiMedx's current Net Loss is estimated to increase to about (31.4 M)
MiMedx Workforce Comparison
MiMedx Group is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 3,184. MiMedx totals roughly 837 in number of employees claiming about 26% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.12 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.12 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.12. MiMedx Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MiMedx insiders, such as employees or executives, is commonly permitted as long as it does not rely on MiMedx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, MiMedx insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 3.6667 | 11 | 3 | 807,717 | 144,977 |
2024-06-01 | 0.875 | 7 | 8 | 173,926 | 65,996 |
2024-03-01 | 1.0 | 6 | 6 | 389,134 | 97,539 |
2023-12-01 | 2.0 | 2 | 1 | 28,200,249 | 90,000 |
2023-06-01 | 0.5625 | 9 | 16 | 347,478 | 129,658 |
2023-03-01 | 1.0 | 6 | 6 | 4,527,771 | 73,670 |
2022-06-01 | 3.0 | 15 | 5 | 1,798,216 | 141,501 |
2021-09-01 | 0.3333 | 1 | 3 | 35,212 | 24,141 |
2021-06-01 | 2.25 | 9 | 4 | 139,815 | 116,081 |
2021-03-01 | 1.3333 | 8 | 6 | 849,051 | 109,356 |
2020-12-01 | 14.0 | 14 | 1 | 310,347 | 301.00 |
2020-09-01 | 4.75 | 19 | 4 | 1,596,902 | 23,476,623 |
2020-03-01 | 0.4 | 2 | 5 | 30,000 | 35,169 |
2019-12-01 | 1.0 | 1 | 1 | 49,295 | 292.00 |
2019-09-01 | 0.3333 | 1 | 3 | 723,154 | 726,565 |
2019-06-01 | 1.75 | 7 | 4 | 1,163,156 | 151,460 |
2019-03-01 | 0.1538 | 2 | 13 | 203,305 | 2,029,277 |
2018-12-01 | 0.3636 | 4 | 11 | 40,000 | 1,466 |
2018-03-01 | 0.3846 | 5 | 13 | 338,900 | 135,952 |
2017-06-01 | 2.4 | 12 | 5 | 531,725 | 166,106 |
2017-03-01 | 0.5 | 5 | 10 | 561,861 | 143,049 |
2016-06-01 | 5.5 | 11 | 2 | 290,003 | 34,695 |
2016-03-01 | 0.5 | 4 | 8 | 292,000 | 28,634 |
2015-12-01 | 7.0 | 7 | 1 | 191,681 | 40,606 |
2015-09-01 | 1.0 | 3 | 3 | 157,235 | 157,235 |
2015-06-01 | 1.0 | 9 | 9 | 190,146 | 283,952 |
2015-03-01 | 0.8 | 8 | 10 | 540,619 | 1,718,736 |
2014-12-01 | 0.4286 | 3 | 7 | 200,000 | 438,065 |
2014-09-01 | 2.125 | 17 | 8 | 318,000 | 269,274 |
2014-03-01 | 3.0 | 9 | 3 | 821,898 | 1,625,000 |
2013-12-01 | 2.0 | 10 | 5 | 994,750 | 838,173 |
2013-09-01 | 0.6429 | 9 | 14 | 1,001,898 | 1,275,463 |
2013-06-01 | 5.0 | 15 | 3 | 166,500 | 100,000 |
2012-12-01 | 1.4444 | 13 | 9 | 1,735,630 | 2,730,290 |
2012-09-01 | 0.7778 | 7 | 9 | 716,372 | 1,633,338 |
2012-06-01 | 0.5 | 1 | 2 | 15,000 | 1,297,000 |
2012-03-01 | 2.8889 | 26 | 9 | 3,450,783 | 976,912 |
2011-09-01 | 1.25 | 5 | 4 | 956,250 | 925,000 |
2010-12-01 | 11.0 | 11 | 1 | 1,651,469 | 280,000 |
2010-03-01 | 7.0 | 14 | 2 | 2,063,998 | 800,000 |
2009-12-01 | 6.1667 | 37 | 6 | 3,103,429 | 484,350 |
2009-09-01 | 3.5 | 35 | 10 | 1,923,622 | 815,815 |
2009-06-01 | 4.0 | 4 | 1 | 685,000 | 200,000 |
2009-03-01 | 1.3333 | 4 | 3 | 2,150,000 | 20,000 |
MiMedx Notable Stakeholders
A MiMedx stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as MiMedx often face trade-offs trying to please all of them. MiMedx's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting MiMedx's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Joseph Capper | CEO Director | Profile | |
Robert MD | President Innovation | Profile | |
Matthew Notarianni | Head Relations | Profile | |
Todd Newton | Interim Director | Profile | |
William Phelan | VP Officer | Profile | |
Kim Moller | Chief Officer | Profile | |
William IV | General Officer | Profile | |
Douglas CPA | Chief Officer | Profile | |
Mark Graves | Chief Compliance Officer | Profile | |
Scott Turner | Senior Procurement | Profile | |
Peter CPA | Chief Officer | Profile | |
David Mason | Chief Officer | Profile | |
Rohit Kashyap | Pres Surgical | Profile | |
Kate Surdez | Chief Officer | Profile | |
Hilary Dixon | Vice Communications | Profile |
About MiMedx Management Performance
The success or failure of an entity such as MiMedx Group often depends on how effective the management is. MiMedx management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of MiMedx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the MiMedx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.18 | 0.19 | |
Return On Capital Employed | 0.27 | 0.28 | |
Return On Assets | 0.16 | 0.17 | |
Return On Equity | 0.22 | 0.21 |
MiMedx Workforce Analysis
Traditionally, organizations such as MiMedx use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare MiMedx within its industry.MiMedx Manpower Efficiency
Return on MiMedx Manpower
Revenue Per Employee | 416.8K | |
Revenue Per Executive | 23.3M | |
Net Income Per Employee | 50.2K | |
Net Income Per Executive | 2.8M | |
Working Capital Per Employee | 174.8K | |
Working Capital Per Executive | 9.8M |
Complementary Tools for MiMedx Stock analysis
When running MiMedx's price analysis, check to measure MiMedx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MiMedx is operating at the current time. Most of MiMedx's value examination focuses on studying past and present price action to predict the probability of MiMedx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MiMedx's price. Additionally, you may evaluate how the addition of MiMedx to your portfolios can decrease your overall portfolio volatility.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |